Abstract
Although predictors of acute intraprocedural stent thrombosis (IPST) in the drug-eluting stent era have been proposed, external validation is lacking. We thus analyzed the occurrence of IPST in the RECIPE study and found that, among 1,320 patients who underwent drug-eluting stent implantation, IPST occurred in 6 (0.5%), with in-hospital major adverse events in 4 (67%). IPST was predicted by number and total length of implanted stents, baseline minimal lumen diameter, and, in a pooled analysis that incorporated values from the present study and a previous study, use of elective glycoprotein IIb/IIIa inhibitors. Such results may provide useful information to guide prevention of this complication.
Publication types
-
Comparative Study
-
Multicenter Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Acute Disease
-
Anticoagulants / therapeutic use
-
Antineoplastic Agents, Phytogenic / therapeutic use*
-
Blood Vessel Prosthesis Implantation / instrumentation*
-
Clopidogrel
-
Coated Materials, Biocompatible*
-
Coronary Angiography
-
Coronary Stenosis / surgery
-
Coronary Thrombosis / diagnosis*
-
Coronary Thrombosis / prevention & control
-
Drug Therapy, Combination
-
Electrocardiography
-
Female
-
Heparin / therapeutic use
-
Humans
-
Intraoperative Complications*
-
Male
-
Middle Aged
-
Paclitaxel / therapeutic use*
-
Platelet Aggregation Inhibitors / therapeutic use
-
Predictive Value of Tests
-
Pyridines / therapeutic use
-
Retrospective Studies
-
Stents*
-
Thrombolytic Therapy
-
Ticlopidine / analogs & derivatives
-
Ticlopidine / therapeutic use
-
Treatment Outcome
Substances
-
Anticoagulants
-
Antineoplastic Agents, Phytogenic
-
Coated Materials, Biocompatible
-
Platelet Aggregation Inhibitors
-
Pyridines
-
thienopyridine
-
Heparin
-
Clopidogrel
-
Ticlopidine
-
Paclitaxel